UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer

Oncogene, 2007-10, Vol.26 (49), p.6997-7005

2007

Volltextzugriff (PDF)

Activation of AKT PKB in breast cancer predicts a worse outcome among endocrine treated patients

British journal of cancer, 2002-02, Vol.86 (4), p.540-545

2002

Volltextzugriff (PDF)

Effects of adjuvant tamoxifen over three decades on breast cancer–free and distant recurrence–free interval among premenopausal women with oestrogen receptor–positive breast cancer randomised in the Swedish SBII:2pre trial

European journal of cancer (1990), 2019-03, Vol.110, p.53-61

2019

Volltextzugriff (PDF)

AIB1 is a predictive factor for tamoxifen response in premenopausal women

Annals of oncology, 2010-02, Vol.21 (2), p.238-244

2010

Volltextzugriff (PDF)

Prognostic utility of HOXB13 : IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial

British journal of cancer, 2011-05, Vol.104 (11), p.1762-1769

2011

Volltextzugriff (PDF)

Phosphorylation of the oestrogen receptor α at serine 305 and prediction of tamoxifen resistance in breast cancer

The Journal of pathology, 2009-02, Vol.217 (3), p.372-379

2009

Volltextzugriff (PDF)

Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial

British journal of cancer, 2011-03, Vol.104 (6), p.899-902

2011

Volltextzugriff (PDF)

Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF

European journal of cancer (1990), 2010, Vol.46 (9), p.1580-1587

2010

Volltextzugriff (PDF)

Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer

Annals of oncology, 2013-08, Vol.24 (8), p.1994-1999

2013

Volltextzugriff (PDF)

Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer

Breast cancer research and treatment, 2016-11, Vol.160 (2), p.313-322

2016

Volltextzugriff (PDF)

Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial

Journal of clinical oncology, 2022-12, Vol.40 (35), p.4071-4082

2022

Volltextzugriff (PDF)

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients

Breast cancer research : BCR, 2005-01, Vol.7 (3), p.R284-R290, Article R284

2005

Volltextzugriff (PDF)

Pegylated liposomal doxorubicin as first-line monotherapy in elderly women with locally advanced or metastatic breast cancer: Novel treatment predictive factors identified

Cancer letters, 2011, Vol.313 (2), p.145-153

2011

Volltextzugriff (PDF)

Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response

BMC cancer, 2014-02, Vol.14 (1), p.119-119, Article 119

2014

Volltextzugriff (PDF)

Identification of intermediate risk breast cancer patients with 1-3 positive lymph nodes and excellent survival after tamoxifen as only systemic adjuvant therapy by use of markers of proliferation and apoptosis

Breast (Edinburgh), 2013-10, Vol.22 (5), p.643-649

2013

Volltextzugriff (PDF)

Akt kinases in breast cancer and the results of adjuvant therapy

Breast cancer research : BCR, 2003-01, Vol.5 (2), p.R37-R44, Article R37

2003

Volltextzugriff (PDF)

Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial

Journal of clinical pathology, 2005-11, Vol.58 (11), p.1135-1142

2005

Volltextzugriff (PDF)

Breast Cancer Index Identifies Early-Stage Estrogen Receptor-Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence

Clinical cancer research, 2013-08, Vol.19 (15), p.4196-4205

2013

Volltextzugriff (PDF)

Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance

Breast cancer research and treatment, 2005-05, Vol.91 (2), p.145-151

2005

Volltextzugriff (PDF)

ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer

Annals of oncology, 2000-12, Vol.11 (12), p.1545-1550

2000

Volltextzugriff (PDF)

Breast cancer hormone receptor levels and benefit from adjuvant tamoxifen in a randomized trial with long-term follow-up

Acta oncologica, 2024-07, Vol.63 (1), p.535-541

2024

Volltextzugriff (PDF)

c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer

European journal of cancer (1990), 1995, Vol.31 (13), p.2185-2190

1995

Volltextzugriff (PDF)

S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer

British journal of cancer, 1994-12, Vol.70 (6), p.1258-1262

1994

Volltextzugriff (PDF)

Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer

BMC cancer, 2021-02, Vol.21 (1), p.185-185, Article 185

2021

Volltextzugriff (PDF)

1 – 25 von 56

Suche als RSS-Feed

Aktive Filter

ThemaBreast Neoplasms - Drug Therapy

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54)
Mit Volltextzugriff
(56)

Publikationsform

Artikel
(56)

Sprache

Englisch
(56)

Erscheinungsjahr

n.n

Thema

Female
(56)
Humans
(56)
Medicin Och Hälsovetenskap
(51)
Science & Technology
(51)
Life Sciences & Biomedicine
(48)
Oncology
(48)
Tamoxifen - Therapeutic Use
(42)
Breast Cancer
(38)
Medicine
(36)
Middle Aged
(32)
Antineoplastic Agents, Hormonal - Therapeutic Use
(31)
Medicin
(31)
Prognosis
(30)
Tamoxifen
(29)
Breast Neoplasms - Metabolism
(26)
Tumors
(26)
Chemotherapy, Adjuvant
(25)
Cancer Och Onkologi
(24)
Adult
(23)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer

Activation of AKT PKB in breast cancer predicts a worse outcome among endocrine treated patients

Effects of adjuvant tamoxifen over three decades on breast cancer–free and distant recurrence–free interval among premenopausal women with oestrogen receptor–positive breast cancer randomised in the Swedish SBII:2pre trial

AIB1 is a predictive factor for tamoxifen response in premenopausal women

Prognostic utility of HOXB13 : IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial

Phosphorylation of the oestrogen receptor α at serine 305 and prediction of tamoxifen resistance in breast cancer

Time dependent effects of adjuvant tamoxifen therapy on cerebrovascular disease: results from a randomised trial

Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF

Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer

Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer

Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients

Pegylated liposomal doxorubicin as first-line monotherapy in elderly women with locally advanced or metastatic breast cancer: Novel treatment predictive factors identified

Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response

Identification of intermediate risk breast cancer patients with 1-3 positive lymph nodes and excellent survival after tamoxifen as only systemic adjuvant therapy by use of markers of proliferation and apoptosis

Akt kinases in breast cancer and the results of adjuvant therapy

Improved survival for women with stage I breast cancer in south-east Sweden: A comparison between two time periods before and after increased use of adjuvant systemic therapy

Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial

Breast Cancer Index Identifies Early-Stage Estrogen Receptor-Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence

Role of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance

ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer

Breast cancer hormone receptor levels and benefit from adjuvant tamoxifen in a randomized trial with long-term follow-up

c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer

S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer

Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer

Aktive Filter

Suchergebnisse filtern